Association between statin therapy and outcomes in critically ill patients: a nested cohort study

Table 2 Association between statin use and primary outcomes compared with the non-statin group using adjusted analyses

	Statin n = 107	Non-statin n = 656	Adjusted odds ratio (aOR)^a	95% confidence interval	P-value
ICU mortality, no. (%)	19/107 (17.8)	108/656 (16.5)	0.84	(0.47 - 1.51)	0.56
Dose < 40 mg	7/47 (14.9)	108/656 (16.5)	0.67	(0.28 - 1.63)	0.43
Dose ≥ 40 mg	12/60 (20.0)	108/656 (16.5)	0.97	(0.48 - 1.99)	0.98
Hospital mortality, no. (%)	42/107 (39.3)	200/656 (30.5)	0.60	(0.36 - 0.99)	0.05
Dose < 40 mg	19/47 (40.4)	200/656 (30.5)	0.69	(0.35 - 1.40)	0.30
Dose ≥ 40 mg	23/60 (38.3)	200/656 (30.5)	0.53	(0.28 - 1.00)	0.05

Variables entered initially in the stepwise regression model including age, gender, admission category, APACHE II score, history of diabetes, creatinine, platelets, GCS, PaO₂/FiO₂, and chronic cardiac, renal, and respiratory diseases.